Format

Send to

Choose Destination
Biol Psychiatry. 2013 Mar 15;73(6):546-54. doi: 10.1016/j.biopsych.2012.09.028. Epub 2012 Nov 13.

Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex.

Author information

1
Department of Pharmacology, Program in Pharmacogenomics, College of Medicine, The Ohio State University, Columbus, OH, USA. Ryan.Smith2@osumc.edu

Abstract

BACKGROUND:

The 5-hydroxytryptamine 2A receptor, encoded by HTR2A, is a major postsynaptic target for serotonin in the human brain and a therapeutic drug target. Despite hundreds of genetic associations investigating HTR2A polymorphisms in neuropsychiatric disorders and therapies, the role of genetic HTR2A variability in health and disease remains uncertain.

METHODS:

To discover and characterize regulatory HTR2A variants, we sequenced whole transcriptomes from 10 human brain regions with massively parallel RNA sequencing and measured allelic expression of multiple HTR2A messenger (m)RNA transcript variants. Following discovery of functional variants, we further characterized their impact on genetic expression in vitro.

RESULTS:

Three polymorphisms modulate the use of novel alternative exons and untranslated regions (UTRs), changing expression of RNA and protein. The frequent promoter variant rs6311, widely implicated in human neuropsychiatric disorders, decreases usage of an upstream transcription start site encoding a longer 5'UTR with greater translation efficiency. rs76665058, located in an extended 3'UTR and unique to individuals of African descent, modulates allelic HTR2A mRNA expression. The third single nucleotide polymorphism, unannotated and present in only a single subject, directs alternative splicing of exon 2. Targeted analysis of HTR2A in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study reveals associations between functional variants and depression severity or citalopram response.

CONCLUSIONS:

Regulatory polymorphisms modulate HTR2A mRNA expression in an isoform-specific manner, directing the usage of novel untranslated regions and alternative exons. These results provide a foundation for delineating the role of HTR2A and serotonin signaling in central nervous system disorders.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00021528.

PMID:
23158458
PMCID:
PMC3582836
DOI:
10.1016/j.biopsych.2012.09.028
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center